Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754467 | 0.81 | PTPN1 (0.42) | PTPN1PTPN2ALDH1A1POLBLMNA | |
| SCHEMBL4278469 | 0.78 | PTPN1 (0.42) | PTPN1PTPN2ALDH1A1POLBRAB9A | |
| SCHEMBL4278463 | 0.77 | PTPN1 (0.42) | PTPN1PTPN2 | |
| SCHEMBL3226424 | 0.74 | PTPN1 (0.45) | PTPN1PTPN2 | |
| SCHEMBL12971491 | 0.73 | PTPN1 (0.47) | PTPN1PTPN2 | |
| SCHEMBL3213368 | 0.73 | PTPN1 (0.49) | PTPN1PTPN2ALDH1A1 | |
| SCHEMBL3212796 | 0.72 | PTPN1 (0.50) | PTPN1PTPN2 | |
| SCHEMBL3222057 | 0.70 | PTPN1 (0.48) | PTPN1PTPN2ALDH1A1POLBTP53 | |
| SCHEMBL3222069 | 0.70 | PTPN1 (0.48) | PTPN1PTPN2ALDH1A1POLBTP53 | |
| SCHEMBL2937152 | 0.69 | PTPN1 (0.49) | PTPN1PTPN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (SZ) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | MUSK, PPP5C, PPP3CA | PTPN1 35/4885PTPN2 49/4885ALDH1A1 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.